Home » Topics » BioWorld Science

BioWorld Science
RSS

Blueprint Medicines and MD Anderson collaborate on advancing CDK2 inhibitor BLU-222

July 29, 2021

FDA clears INDs for targeted alpha therapy FPI-1966 and imaging agent FPI-1967

July 29, 2021

Daewoong reports phase IIb topline data on Foistar in mild COVID-19

July 29, 2021

Restoring chondroitin 6-sulfate can rescue age-related memory impairment

July 29, 2021

Clarity initiates phase I/IIa theranostic trial of 64/67Cu SAR-bisPSMA in metastatic CRPC

July 29, 2021

Arcturus cleared to begin phase II study of ARCT-810 for OTC deficiency

July 29, 2021

Venatorx reports phase I data on beta-lactamase inhibitor VNRX-7145

July 29, 2021

New phase Ib/II trial evaluates pembrolizumab combination therapies in second-line ES-SCLC

July 29, 2021

Targeting the IL-8/CXCR2 axis as a potential therapeutic strategy in prostate cancer

July 29, 2021

IDMC of phase II study of EscharEx for venous leg ulcers recommends continuation of trial

July 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...